Authors not listed had no disclosures to report. S.A.P.: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, T.G. Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. S.A.P. has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, GlaxoSmithKline, Verastem Oncology, and AbbVie (he was not personally compensated for his participation). M.V.S.: Consultancy for Dren Bio. N.N.B.: Advisory board for Verastem. A.A.: Research support to institution from Novartis, Celgene/BMS, Medimmune, Onconova, Astex, H3 Biomedicine, Daiichi-Sankyo, Aprea. Y.W.: Research funding (provided to the institution) from Incyte, InnoCare, and Novartis. S.S.K.: Research funding from Novartis, Humanigen, Kite, Gilead, Juno, Celgene, Tolero, Lentigen, MorphoSys, Sunesis. Patents and royalties to Novartis, Humanigen, Mettaforge. Advisory board membership for Kite, Humanigen, Juno. N.E.K.: Research funding from Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. Data Safety Monitoring Committee for Agios Pharm, AstraZeneca, BMS-Celgene, Cytomx Therapeutics, Morpho-sys, Rigel. Advisory board for Abbvie, AstraZeneca, Cytomx Therapy, Dava Oncology, Juno Therapeutics, Oncotracker, Pharmacyclics. W.D.: Research funding has been provided to the institution from Merck, AbbVie and DTRM. WD has participated in advisory board meetings of Octapharma, Beigene, MEI pharma and Alexion (she was not personally compensated for her participation).